CyVek Inc. has secured $3 million in funding, according to federal documents. 22 separate investors participated in the offering.

CyVek, Inc. is engaged in the development of a novel, platform technology for measuring analytes in biological samples. The objective of the CyVek technology is to provide a robust platform for multiplexed proteomics, particularly to serve the market needs of biomarker validation. With its world-class team of engineers and scientists, CyVek plans to leverage its innovative and proprietary approach throughout the life sciences and clinical diagnostics fields.